CELC 주가 차트
CELC 재무
Celcuity Inc
$92.08
4.5%
$3.96
종가: Aug 12, 16:00:00 GMT-4
$90.24
-1.99%
$-1.84
애프터마켓: Aug 12, 20:00:00 GMT-4
뒤로
Celcuity Inc (CELC) 재무
주요 통계
이전 종가
$88.11
시가
$88.72
일일 범위
$88.05 - $92.56
52주 범위
$13.47 - $151.02
거래량
795.2K
평균 거래량
1.3M
배당수익률
--
EPS(TTM)
-3.90
시가총액
$4.4B
CELC란 무엇인가요?
Celcuity, Inc. operates as a cellular analysis company. The company is headquartered in Minneapolis, Minnesota and currently employs 155 full-time employees. The company went IPO on 2017-09-20. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.
